Effects and Safety of Ginsenoside Rg3 combined with Transarterial Chemoembolization Therapy for Patients with Liver Cancers

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001643

Enrollment

Unknown

Registered

2011-10-20

Start date

2011-10-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Rg3:TACE+Rg3

control:TACE

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: liver cancer patients who undertake TACE

Exclusion criteria

Exclusion criteria: servere liver and renal dysfunction; allergic to Ginsenoside; survival time less than 3 months

Design outcomes

Primary

Measure	Time frame
overall survival (OS);	—

Countries

China

Contacts

Public ContactZhou Bo

bonheurzhou@hotmail.com+86 13621604953

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 2, 2026